School of Pharmacy

Rodney Ho

Professor, Department of Pharmaceutics, Bioengineering (Adjunct) and Director of the Targeted Long-Acting Combination Antiretroviral Therapy (TLC- ART) Program; Affiliate Member of Clinical Pharmacology, Fred Hutchinson Cancer Research Center; Affiliate Faculty, UW Center for AIDS Research and a member of the Institute of Translational Health Services

Department of Pharmaceutics, Pharmaceutics Faculty, School Faculty

Telephone: (206) 543-9434


Website: TLC-ART Program Website

Expertise: Biotechnology, Computational Modeling, Drug Metabolism, HIV and AIDS, Infectious Diseases, Long-acting therapeutics, Long-Acting Therapeutics for Chronic Diseases, Mass Spectrometry, Mechanisms-of-Drug-Interactions, Nanomedicine, Oncology, Pharmacokinetics-Pharmacodynamics, Systems Pharmacology, Targeted (drug-combination) therapy, Targeted Drug Delivery


  • PhD, University of Tennessee
  • Bachelor of Science, University of California
  • Post-Doctoral Fellow, Stanford University Internal Medicine

Research Interests

Dr. Ho is known for biotechnology and nanotechnology research and education that enable transformation of basic biomedical discovery into therapeutics. In addition to innovations in drug formulations, his research focuses on biology and treatments of cancer and viral infectious diseases. Some topics include (1) Systems approach to drug and protein transport, delivery, and drug targeting to improve efficacy and safety; (2) Drug-interaction and genetic basis of inter-individual variations in AIDS and cancer therapies; (3) Drug and lipid or biomaterial interaction studies that enable engineering and development of long acting and targeted systems that enhance drug potency and safety.


Dr. Ho is a professor and presidential entrepreneurial fellow of the University of Washington, and holds appointments at the Fred Hutchinson Cancer Research Center. He is also an expert on pharmacology and systems approach to drug targeting and long-acting therapy. His research aims to improve the therapeutic efficacy and safety of viral and cancer drugs, medical diagnostic agents and vaccines. He is an elected fellow of the American Association for the Advancement of Science (AAAS) and the American Association of Pharmaceutical Scientists (AAPS). He studies the relationships between drug target distribution and its relationship to disease development in cancer, AIDS, and neurological disorders. Building on this understanding, he has developed a systems Approach to Drug Delivery and Targeting. He is known for his expertise in bio-therapeutics, lipid-drug and -protein interactions, liposomes, drug-combination nanoparticles, pharmacokinetics, and the interplay between tissue targets and drug penetration. His research has led to enhanced HIV, cancer, and pain medication potency and safety. In addition, he is an editor of the Journal of Pharmaceutical Sciences, and author of “Biotechnology and Biopharmaceuticals: Transforming Proteins and Gene into Drugs.” He has received top honors including the Paul Dawson Biotechnology life-time achievement award, and the AAPS Biotechnology Research achievement, one of AAPS’s highest recognitions.

Selected Publications

PubMed link

Ho, R.J.Y., and Gibaldi, M. “Biotechnology and Biopharmaceuticals: Transforming proteins and genes into drugs,” John Wiley and Sons, N.Y., June 2003; 2nd edition published in 2013.

Ho RJ. “Midyear Commentary on Trends in Drug Delivery and Clinical Translational Medicine: Growth in Biosimilar (Complex Injectable Drug Formulation) Products Within Evolving Collaborative Regulatory Interagency (FDA, FTC, and DOJ) Practices and Enforcement. J Pharm Sci. 2017 Feb;106(2):471-476.

Crouthamel MH, Kelly, E and Ho RJY. Development of Transgenic Mouse Models for Conditional Gene Knockout in the Blood-Brain and Blood-CSF Barriers, Transgenic Res.21 (1):113-30. 2012.

Kraft JC, McConnachie LA, Koehn J, Kinman L, Collins C, Shen DD, Collier AC, Ho RJ. “Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma”. AIDS. 2017 Mar 27;31(6):765-770.

Kraft, JC, Freeling, JP, Wang, Z and Ho, RJY. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci 103: 29-52. 2014.

Freeling, JP, Koehn, J, Shu, J, Sun, J and Ho, RJY. Long-Acting Three-Drug Combination Anti-HIV Nanoparticles Enhance Drug Exposure in Primate Plasma and Cells within Lymph Nodes and Blood. AIDS 28: 2625-2631, 2015 (highlighted by an accompanying editorial commentary in AIDS)

Shao J, Kraft JC, Li B, Yu J, Freeling J, Koehn J, Ho RJ. “Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS.” Nanomedicine (Lond). 2016;11(5):545-64